Is Novo Nordisk (CPSE:NOVO B) Undervalued Following CEO Obesity Market Comments?
Novo Nordisk (CPSE:NOVO B) is back in focus after its CEO argued that investors may be undervaluing the long term potential of obesity treatments, along with fresh signals on the company’s shareholder return plans.
See our latest analysis for Novo Nordisk.
Novo Nordisk’s recent CEO comments and ongoing buyback and dividend plans come after a mixed run, with the share price up 2.76% over 90 days but down 10.17% over 30 days and the 1 year total shareholder return declining 10.80%, while the 3 year total shareholder return is down 49.15%.
If this obesity and diabetes focus has your attention, it can be useful to see what else is moving in related areas, including 131 healthcare AI stocks.
After a strong multiyear run followed by a sharp pullback, Novo Nordisk now sits between two camps. Has most of the obesity and diabetes story already been priced in, or is there still meaningful upside left on today’s valuation?
Most Popular Narrative: 65.2% Undervalued
The current Novo Nordisk share price of DKK296.35 sits well below a narrative fair value of DKK851.04, which frames the stock as heavily discounted and places emphasis on long term obesity and diabetes opportunities.
Novo Nordisk has built a formidable economic moat ("Burggraben") through decades of expertise in diabetes care, world-class manufacturing, and a trusted global brand. With the unexpected success of its obesity drugs, the company has effectively gained a highly profitable new business segment almost for free, built on the same scientific platform.
Want to see why this valuation leans so far above today’s price? The narrative relies on strong revenue expansion, firm margins and a future earnings multiple that assumes Novo Nordisk keeps its obesity and diabetes engine working hard. Curious which specific assumptions combine to reach that DKK851.04 fair value and how they compare with recent returns?
Result: Fair Value of DKK851.04 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the narrative could be challenged if obesity pricing pressure intensifies, or if Eli Lilly’s competing GLP-1 drugs capture more long term market share.
Find out about the key risks to this Novo Nordisk narrative.
Next Steps
Given the mix of optimism and concern around Novo Nordisk, it helps to move quickly and test the story against the numbers yourself. To weigh both sides in one place, start with the 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Novo Nordisk?
Do not stop with Novo Nordisk. Broaden your watchlist now so you are not relying on a single story when the next opportunity moves quickly.
- Target potential mispricings and widen your opportunity set with 264 high quality undervalued stocks.
- Strengthen your income foundation by reviewing companies in the 435 dividend fortresses.
- Prioritise resilience and sleep easier at night by checking the 289 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com